Institutional members access full text with Ovid®

Share this article on:

External Validity of the Cardiovascular Health Study: A Comparison With the Medicare Population

DiMartino, Lisa D. MPH*; Hammill, Bradley G. MS*; Curtis, Lesley H. PhD*†; Gottdiener, John S. MD; Manolio, Teri A. MD, PhD§; Powe, Neil R. MD, MPH, MBA**¶∥; Schulman, Kevin A. MD*†

doi: 10.1097/MLR.0b013e318197b104
Original Article

Background: The Cardiovascular Health Study (CHS), a population-based prospective cohort study, has been used to identify major risk factors associated with cardiovascular disease and stroke in the elderly.

Objective: To assess the external validity of the CHS.

Research Design: Comparison of the CHS cohort to a national cohort of Medicare beneficiaries and to Medicare beneficiaries residing in the CHS geographic regions.

Subjects: CHS participants and a 5% sample of Medicare beneficiaries.

Measures: Demographic and administrative characteristics, comorbid conditions, resource use, and mortality.

Results: Compared with both Medicare cohorts, the CHS cohort was older and included more men and African American participants. CHS participants were more likely to be enrolled in Medicare managed care than beneficiaries in the national Medicare cohort. Compared with the Medicare cohorts, mortality in the CHS was more than 40% lower at 1 year, approximately 25% lower at 5 years, and approximately 15% lower at 10 years. There were minimal differences in comorbid conditions and health care resource use.

Conclusion: The CHS cohort is comparable with the Medicare population, particularly with regard to comorbid conditions and resource use, but had lower mortality. The difference in mortality may reflect the CHS recruitment strategy or volunteer bias. These findings suggest it may not be appropriate to project absolute rates of disease and outcomes based on CHS data to the entire Medicare population. However, there is no reason to expect that the relative risks associated with physiologic processes identified by CHS data would differ for nonparticipants.

From the *Center for Clinical and Genetic Economics, Duke Clinical Research Institute, and †Department of Medicine, Duke University School of Medicine, Durham, North Carolina; ‡Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland; §Office of Population Genomics, National Human Genome Research Institute, Bethesda, Maryland; ¶Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland; ∥Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and **Departments of Epidemiology and Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Supported by contracts N01HC85079 through N01HC85086, N01HC35129, N01HC15103, N01HC55222, N01HC75150, and N01HC45133 and grant U01HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke.

A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm.

Reprints: Lesley H. Curtis, PhD, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail: lesley.curtis@duke.edu.

© 2009 Lippincott Williams & Wilkins, Inc.